Estrigenix type.png

Estrigenix is striving to improve women’s health through targeted chemistry

Microscope Picture.jpg

Our Mission

Estrigenix is a privately held pharmaceutical company leading the way of research and progress in estrogen biology. We are currently working on a compound to specifically help female patients prevent the symptoms of Alzheimer’s disease from developing. Our mission is to develop a drug that is able to help women live healthier and longer lives. Our end goal is to develop an understanding as to how and why Alzheimer’s Disease is more common for women than for men.

Learn More


Our Product

The global hormone therapy market is estimated to reach a value of $28.2 billion by 2022 with estrogen-based products leading in market revenues.



Million women Affected

There are 5.5 million people living with Alzheimer’s in the U.S. and 3.4 million women.



60% of all Alzheimer’s caregivers are women

The greatest known risk factor is increasing age, and the majority of people with Alzheimer's are 65 and older, but there is approximately 200,000 Americans under the age of 65 have younger-onset Alzheimer’s disease.



Alzheimer’s is a real possibility

Research has found that women in their 60s are twice as likely to develop Alzheimer’s than to develop breast cancer.


Learn more about estrigenix in the news today!